Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Related Citations for PubMed (Select 23657825)

1.

The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis.

Thomas SK, Hodson J, McIlroy G, Dhami A, Coleman JJ.

Drug Saf. 2013 Jul;36(7):557-64. doi: 10.1007/s40264-013-0057-3.

PMID:
23657825
2.

Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011.

Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR.

PLoS One. 2013 Jul 17;8(7):e68976. doi: 10.1371/journal.pone.0068976. Print 2013.

3.

Impact of safety-related regulatory action on clinical practice: a systematic review.

Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG.

Drug Saf. 2012 May 1;35(5):373-85. doi: 10.2165/11599100-000000000-00000. Review.

PMID:
22480319
4.

[Impact of pharmacotherapeutic warnings on the prescription of clopidogrel and proton pump inhibitors in hospitalised patients].

Sánchez Ruiz-Gordoa M, Tenías Burillo JM, Ruiz Martín de la Torre R, Valenzuela Gámez JC.

Farm Hosp. 2012 Jul-Aug;36(4):250-5. Epub 2011 Nov 25. Spanish.

PMID:
22118768
5.

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM.

Drug Saf. 2010 Jun 1;33(6):463-74. doi: 10.2165/11532840-000000000-00000.

PMID:
20486729
6.

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH.

Drug Saf. 2012 Jun 1;35(6):471-80. doi: 10.2165/11596950-000000000-00000.

PMID:
22540371
7.

When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines.

Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG.

Clin Pharmacol Ther. 2013 Apr;93(4):360-5. doi: 10.1038/clpt.2012.262. Epub 2012 Dec 27.

PMID:
23443752
8.

Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing.

McIlroy G, Thomas SK, Coleman JJ.

J Public Health (Oxf). 2014 Mar 28. [Epub ahead of print]

PMID:
24681910
9.
10.

Clopidogrel and PPI interaction: clinically relevant or not?

Harrison RW, Mahaffey KW.

Curr Cardiol Rep. 2012 Feb;14(1):49-58. doi: 10.1007/s11886-011-0233-y. Review.

PMID:
22090195
11.

A practice-based approach for converting from proton pump inhibitors to less costly therapy.

Lucas LM, Gerrity MS, Anderson T.

Eff Clin Pract. 2001 Nov-Dec;4(6):263-70.

12.

Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.

Sanfélix-Gimeno G, Cervera-Casino P, Peiró S, López-Valcarcel BG, Blázquez A, Barbera T.

Drug Saf. 2009;32(11):1075-87. doi: 10.2165/11316520-000000000-00000.

PMID:
19810779
13.

Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.

Kwok CS, Loke YK.

Drug Saf. 2012 Feb 1;35(2):127-39. doi: 10.2165/11594900-000000000-00000. Review.

PMID:
22204719
14.

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2009 Apr;101(4):714-9.

PMID:
19350116
15.

Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.

Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, Berliner S, Deutsch V, Herz I, Keren G, Banai S.

Clin Cardiol. 2013 Jun;36(6):342-6. doi: 10.1002/clc.22117. Epub 2013 Apr 29.

PMID:
23630016
16.

Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.

Mahabaleshwarkar RK, Yang Y, Datar MV, Bentley JP, Strum MW, Banahan BF, Null KD.

Curr Med Res Opin. 2013 Apr;29(4):315-23. doi: 10.1185/03007995.2013.772051. Epub 2013 Feb 11.

PMID:
23362935
17.
18.

Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.

Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS.

Br J Clin Pharmacol. 2012 Nov;74(5):824-34. doi: 10.1111/j.1365-2125.2012.04250.x.

19.

Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG.

Drug Saf. 2012 Nov 1;35(11):1061-72. doi: 10.2165/11635750-000000000-00000.

PMID:
23061782
20.

Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations.

Abraham NS.

Curr Opin Gastroenterol. 2011 Oct;27(6):558-64. doi: 10.1097/MOG.0b013e32834a382e. Review.

PMID:
22001826
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk